Prevalence of prediabetes, diabetes among adolescents on the rise
NEW YORK — Being overweight and obesity during adolescence are associated with an increased risk for cardiovascular disease risk factors, especially prediabetes and diabetes, according to researchers.
Analyzing data from the National Health and Nutrition Examination Survey, researchers found that among adolescents ages 12 too 19 years, the prevalence of prediabetes/diabetes increased from 9% in the 1999-2000 NHANES to 23% during the 2007-2008 NHANES. While prediabetes/diabetes experienced an increase, the researchers also noted that other CVD risk factors — such as prehypertension/hypertension (17% and 13%) and borderline-high/high low-density lipoprotein cholesterol (23% and 19%) — saw no significant change when observed in the 1999-2000 NHANES and 2007-2008 NHANES.
The results were published in Pediatrics.
Novo Nordisk’s Levemir approved for children ages 2 to 5 years
PRINCETON, N.J. — The Food and Drug Administration has approved a treatment for Type 1 diabetes in children ages 2 to 5 years.
Drug maker Novo Nordisk announced Tuesday the additional approval of Levemir (insulin detemir [rDNA origin]). The insulin already was approved for Type 1 diabetes in older children and adults and Type 2 diabetes in adults, and the drug maker said the new FDA approval made Levemir the only basal insulin analog for use in the 2 to 5 year age group.
"Our biggest challenges and top priorities when treating some of the youngest children with Type 1 diabetes are safety and reducing the risk of hypoglycemia," said, Mark Sperling, editor-in-chief of the journal Pediatric Diabetes, referring to low blood sugar. "Levemir, with its approval from the FDA, is a particularly welcome addition to our treatment options for some of our youngest patients with Type 1 diabetes."
BD introduces syringe with smaller needle for diabetes patients
FRANKLIN LAKES, N.J. — Medical supply manufacturer BD has released a syringe with a shorter needle designed to reduce discomfort in patients with diabetes who must inject insulin, the company said Tuesday.
BD announced the introduction of the ultra-fine 6mm needle, saying more than 80% of patients expressed a preference for it in trials, and a recent article published by the American Association of Diabetes Educators recognized the safety and efficacy of shorter needles.
The needle is designed to deliver insulin subcutaneously in adults and children.